Molecular determinants of altered Ca2+ handling in human chronic atrial fibrillation.

Standard

Molecular determinants of altered Ca2+ handling in human chronic atrial fibrillation. / El-Armouche, Ali; Boknik, Peter; Eschenhagen, Thomas; Carrier, Lucie; Knaut, Michael; Ravens, Ursula; Dobrev, Dobromir.

In: CIRCULATION, Vol. 114, No. 7, 7, 2006, p. 670-680.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

El-Armouche, A, Boknik, P, Eschenhagen, T, Carrier, L, Knaut, M, Ravens, U & Dobrev, D 2006, 'Molecular determinants of altered Ca2+ handling in human chronic atrial fibrillation.', CIRCULATION, vol. 114, no. 7, 7, pp. 670-680. <http://www.ncbi.nlm.nih.gov/pubmed/16894034?dopt=Citation>

APA

El-Armouche, A., Boknik, P., Eschenhagen, T., Carrier, L., Knaut, M., Ravens, U., & Dobrev, D. (2006). Molecular determinants of altered Ca2+ handling in human chronic atrial fibrillation. CIRCULATION, 114(7), 670-680. [7]. http://www.ncbi.nlm.nih.gov/pubmed/16894034?dopt=Citation

Vancouver

El-Armouche A, Boknik P, Eschenhagen T, Carrier L, Knaut M, Ravens U et al. Molecular determinants of altered Ca2+ handling in human chronic atrial fibrillation. CIRCULATION. 2006;114(7):670-680. 7.

Bibtex

@article{59423e8dabc2458cae2bc91cff27f42b,
title = "Molecular determinants of altered Ca2+ handling in human chronic atrial fibrillation.",
abstract = "BACKGROUND: Abnormal Ca2+ handling may contribute to impaired atrial contractility and arrhythmogenesis in human chronic atrial fibrillation (cAF). Here, we assessed the phosphorylation levels of key proteins involved in altered Ca2+ handling and contractility in cAF patients. METHODS AND RESULTS: Total and phosphorylation levels of Ca2+-handling and myofilament proteins were analyzed by Western blotting in right atrial appendages of 49 patients in sinus rhythm and 52 cAF patients. We found a higher total activity of type 1 (PP1) and type 2A phosphatases in cAF, which was associated with inhomogeneous changes of protein phosphorylation in the cellular compartments, ie, lower protein kinase A (PKA) phosphorylation of myosin binding protein-C (Ser-282 site) at the thick myofilaments but preserved PKA phosphorylation of troponin I at the thin myofilaments and enhanced PKA (Ser-16 site) and Ca2+-calmodulin protein kinase (Thr-17 site) phosphorylation of phospholamban. PP1 activity at sarcoplasmic reticulum is controlled by inhibitor-1 (I-1), which blocks PP1 in its PKA-phosphorylated form only. In cAF, the ratio of Thr-35-phosphorylated to total I-1 was 10-fold higher, which suggests that the enhanced phosphorylation of phospholamban may result from a stronger PP1 inhibition by PKA-hyperphosphorylated (activated) I-1. CONCLUSIONS: Altered Ca2+ handling in cAF is associated with impaired phosphorylation of myosin binding protein-C, which may contribute to the contractile dysfunction after cardioversion. The hyperphosphorylation of phospholamban probably results from enhanced inhibition of sarcoplasmic PP1 by hyperphosphorylated I-1 and may reinforce the leakiness of ryanodine channels in cAF. Restoration of sarcoplasmic reticulum-associated PP1 function may represent a new therapeutic option for treatment of atrial fibrillation.",
author = "Ali El-Armouche and Peter Boknik and Thomas Eschenhagen and Lucie Carrier and Michael Knaut and Ursula Ravens and Dobromir Dobrev",
year = "2006",
language = "Deutsch",
volume = "114",
pages = "670--680",
journal = "CIRCULATION",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

RIS

TY - JOUR

T1 - Molecular determinants of altered Ca2+ handling in human chronic atrial fibrillation.

AU - El-Armouche, Ali

AU - Boknik, Peter

AU - Eschenhagen, Thomas

AU - Carrier, Lucie

AU - Knaut, Michael

AU - Ravens, Ursula

AU - Dobrev, Dobromir

PY - 2006

Y1 - 2006

N2 - BACKGROUND: Abnormal Ca2+ handling may contribute to impaired atrial contractility and arrhythmogenesis in human chronic atrial fibrillation (cAF). Here, we assessed the phosphorylation levels of key proteins involved in altered Ca2+ handling and contractility in cAF patients. METHODS AND RESULTS: Total and phosphorylation levels of Ca2+-handling and myofilament proteins were analyzed by Western blotting in right atrial appendages of 49 patients in sinus rhythm and 52 cAF patients. We found a higher total activity of type 1 (PP1) and type 2A phosphatases in cAF, which was associated with inhomogeneous changes of protein phosphorylation in the cellular compartments, ie, lower protein kinase A (PKA) phosphorylation of myosin binding protein-C (Ser-282 site) at the thick myofilaments but preserved PKA phosphorylation of troponin I at the thin myofilaments and enhanced PKA (Ser-16 site) and Ca2+-calmodulin protein kinase (Thr-17 site) phosphorylation of phospholamban. PP1 activity at sarcoplasmic reticulum is controlled by inhibitor-1 (I-1), which blocks PP1 in its PKA-phosphorylated form only. In cAF, the ratio of Thr-35-phosphorylated to total I-1 was 10-fold higher, which suggests that the enhanced phosphorylation of phospholamban may result from a stronger PP1 inhibition by PKA-hyperphosphorylated (activated) I-1. CONCLUSIONS: Altered Ca2+ handling in cAF is associated with impaired phosphorylation of myosin binding protein-C, which may contribute to the contractile dysfunction after cardioversion. The hyperphosphorylation of phospholamban probably results from enhanced inhibition of sarcoplasmic PP1 by hyperphosphorylated I-1 and may reinforce the leakiness of ryanodine channels in cAF. Restoration of sarcoplasmic reticulum-associated PP1 function may represent a new therapeutic option for treatment of atrial fibrillation.

AB - BACKGROUND: Abnormal Ca2+ handling may contribute to impaired atrial contractility and arrhythmogenesis in human chronic atrial fibrillation (cAF). Here, we assessed the phosphorylation levels of key proteins involved in altered Ca2+ handling and contractility in cAF patients. METHODS AND RESULTS: Total and phosphorylation levels of Ca2+-handling and myofilament proteins were analyzed by Western blotting in right atrial appendages of 49 patients in sinus rhythm and 52 cAF patients. We found a higher total activity of type 1 (PP1) and type 2A phosphatases in cAF, which was associated with inhomogeneous changes of protein phosphorylation in the cellular compartments, ie, lower protein kinase A (PKA) phosphorylation of myosin binding protein-C (Ser-282 site) at the thick myofilaments but preserved PKA phosphorylation of troponin I at the thin myofilaments and enhanced PKA (Ser-16 site) and Ca2+-calmodulin protein kinase (Thr-17 site) phosphorylation of phospholamban. PP1 activity at sarcoplasmic reticulum is controlled by inhibitor-1 (I-1), which blocks PP1 in its PKA-phosphorylated form only. In cAF, the ratio of Thr-35-phosphorylated to total I-1 was 10-fold higher, which suggests that the enhanced phosphorylation of phospholamban may result from a stronger PP1 inhibition by PKA-hyperphosphorylated (activated) I-1. CONCLUSIONS: Altered Ca2+ handling in cAF is associated with impaired phosphorylation of myosin binding protein-C, which may contribute to the contractile dysfunction after cardioversion. The hyperphosphorylation of phospholamban probably results from enhanced inhibition of sarcoplasmic PP1 by hyperphosphorylated I-1 and may reinforce the leakiness of ryanodine channels in cAF. Restoration of sarcoplasmic reticulum-associated PP1 function may represent a new therapeutic option for treatment of atrial fibrillation.

M3 - SCORING: Zeitschriftenaufsatz

VL - 114

SP - 670

EP - 680

JO - CIRCULATION

JF - CIRCULATION

SN - 0009-7322

IS - 7

M1 - 7

ER -